Clovis Oncology, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 24 rows in 2020. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-12-15: Reporting owner Rolfe Lindsey; Form 4; Security Employee Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-12-10: Reporting owner IVERS-READ GILLIAN C; Form 4; Security Employee Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-12-07: Reporting owner Harding Thomas C.; Form 3; Security Stock Option (right to buy); Transaction Holding.
- 2020-12-07: Reporting owner Harding Thomas C.; Form 3; Security Stock Option (right to buy); Transaction Holding.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-12-15 | Rolfe Lindsey Officer (See Remarks) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −17,241 0 owned after | $3.28 exercise price | 2020-12-16 | |
| 2020-12-10 | IVERS-READ GILLIAN C Officer (See Remarks) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −68,965 0 owned after | $3.28 exercise price | 2020-12-14 | |
| 2020-12-07 holding as of filing | Harding Thomas C. Officer (See Remarks) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $73.98 exercise price | 2020-12-07 | ||
| 2020-12-07 holding as of filing | Harding Thomas C. Officer (See Remarks) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $78.38 exercise price | 2020-12-07 | ||
| 2020-12-07 holding as of filing | Harding Thomas C. Officer (See Remarks) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $79.05 exercise price | 2020-12-07 | ||
| 2020-12-07 holding as of filing | Harding Thomas C. Officer (See Remarks) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $85.88 exercise price | 2020-12-07 | ||
| 2020-12-07 holding as of filing | Harding Thomas C. Officer (See Remarks) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $22.73 exercise price | 2020-12-07 | ||
| 2020-12-07 holding as of filing | Harding Thomas C. Officer (See Remarks) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $59.27 exercise price | 2020-12-07 | ||
| 2020-12-07 holding as of filing | Harding Thomas C. Officer (See Remarks) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $58.43 exercise price | 2020-12-07 | ||
| 2020-12-07 holding as of filing | Harding Thomas C. Officer (See Remarks) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $3.40 exercise price | 2020-12-07 | ||
| 2020-11-09 | ATWOOD BRIAN G Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,896 0 owned after | $3.08 exercise price | 2020-11-10 | |
| 2020-06-04 | GRAHAM GINGER L Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,138 40,138 owned after | $6.48 exercise price | 2020-06-08 | |
| 2020-06-04 | Fair Richard A. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,138 40,138 owned after | $6.48 exercise price | 2020-06-08 | |
| 2020-06-04 | ATWOOD BRIAN G Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,138 40,138 owned after | $6.48 exercise price | 2020-06-05 | |
| 2020-06-04 | Flaherty Keith T. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,138 40,138 owned after | $6.48 exercise price | 2020-06-05 | |
| 2020-06-04 | McKinley Edward J Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,138 40,138 owned after | $6.48 exercise price | 2020-06-05 | |
| 2020-06-04 | Azelby Robert Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,138 40,138 owned after | $6.48 exercise price | 2020-06-05 | |
| 2020-06-04 | KLINGENSTEIN PAUL H Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,138 40,138 owned after | $6.48 exercise price | 2020-06-05 | |
| 2020-06-04 | SPICKSCHEN THORLEF Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,138 40,138 owned after | $6.48 exercise price | 2020-06-05 | |
| 2020-06-04 | BLAIR JAMES C Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,138 40,138 owned after | $6.48 exercise price | 2020-06-05 | |
| 2020-04-06 | Rolfe Lindsey Officer (See Remarks) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −23,034 0 owned after | $3.08 exercise price | 2020-04-08 | |
| 2020-02-13 | MAHAFFY PATRICK J Director, Officer (President and CEO) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $9.71 exercise price | 2020-02-18 | |
| 2020-02-03 | MAHAFFY PATRICK J Director, Officer (President and CEO) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,000 200,000 owned after | $8.39 exercise price | 2020-02-03 | |
| 2020-02-03 | MAHAFFY PATRICK J Director, Officer (President and CEO) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $8.39 exercise price | 2020-02-03 |